William Blair Issues Optimistic Outlook for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at William Blair upped their Q2 2025 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, May 14th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.09) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics’ Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.29) EPS.

A number of other research firms have also recently issued reports on ZVRA. Guggenheim lifted their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Canaccord Genuity Group increased their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, May 14th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday, March 13th. Finally, JMP Securities set a $18.00 target price on Zevra Therapeutics in a research report on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $22.29.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $8.61 on Monday. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The company has a market capitalization of $470.79 million, a price-to-earnings ratio of -4.37 and a beta of 1.87. The company has a 50-day simple moving average of $7.57 and a 200 day simple moving average of $8.08.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the firm posted ($0.40) EPS.

Insiders Place Their Bets

In related news, Director John B. Bode bought 10,000 shares of Zevra Therapeutics stock in a transaction on Wednesday, March 19th. The stock was acquired at an average price of $7.96 per share, with a total value of $79,600.00. Following the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at $318,400. This represents a 33.33% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in Zevra Therapeutics by 292.6% during the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after buying an additional 42,926 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Zevra Therapeutics by 51.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company’s stock valued at $172,000 after buying an additional 6,966 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Zevra Therapeutics by 50.5% during the 4th quarter. JPMorgan Chase & Co. now owns 27,490 shares of the company’s stock valued at $229,000 after buying an additional 9,225 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Zevra Therapeutics during the 4th quarter valued at about $224,000. Finally, Rhumbline Advisers grew its holdings in shares of Zevra Therapeutics by 18.4% during the fourth quarter. Rhumbline Advisers now owns 68,053 shares of the company’s stock worth $568,000 after purchasing an additional 10,573 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.